Danaher Corporation (DHR)vsInsight Molecular Diagnostics Inc. (IMDX)
DHR
Danaher Corporation
$200.14
-0.19%
HEALTHCARE · Cap: $140.97B
IMDX
Insight Molecular Diagnostics Inc.
$4.20
+5.53%
HEALTHCARE · Cap: $131.22M
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 1503313% more annual revenue ($25.11B vs $1.67M). DHR leads profitability with a 16.0% profit margin vs 0.0%. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
IMDX
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.9%
Fair Value
$118.49
Current Price
$200.14
$81.65 premium
Intrinsic value data unavailable for IMDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : IMDX
The strongest argument for IMDX centers on Debt/Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : IMDX
The primary concerns for IMDX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
DHR profiles as a mature stock while IMDX is a value play — different risk/reward profiles.
IMDX carries more volatility with a beta of 1.82 — expect wider price swings.
DHR is growing revenue faster at 5.5% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 17/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Insight Molecular Diagnostics Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?